TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the first quarter ended March 31, 2025, and provides a corporate update on its recent activities and upcoming milestones.
The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2025, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.